German Hepatitis C-Registry (DHC-R)

Conditions

B18.2

Wilhelm LM, Stoehr A, Buggisch P, John C, Link R, Klinker H, Merle U, Cornberg M, Sarrazin C, Berg T, Wedemeyer H.

2026-06-01

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Jenny Bischoff, Stefan Mauss, Thomas A. Lutz, Christiane Cordes, Gerd Klausen et al. (11 authors)

Journal of Viral Hepatitis2021-07-213 citations

10.1111/jvh.13576

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

Frank Tacke, Klaus Boeker, Hartwig Klinker, R Heyne, Peter Buggisch et al. (12 authors)

Liver International2019-06-2632 citations

10.1111/liv.14186

Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry

Thomas Berg, Uwe Naumann, Albrecht Stoehr, C. Sick, Christine John et al. (12 authors)

Alimentary Pharmacology & Therapeutics2019-03-1573 citations

10.1111/apt.15222

Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.

Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK.

2018-12-012 citations

10.1080/15284336.2018.1538193

Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry.

Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Hüppe D, Böker K, Wedemeyer H, Welzel TM, Leberstiftungs-GmbH Deutschland.

2018-09-0111 citations

10.1007/s40266-018-0572-0

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.

Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, Boeker K, Zimmermann T, Teuber G, Vornkahl HP, Simon KG, Niederau C, Wedemeyer H, Zeuzem S.

2017-11-1139 citations

10.1016/j.jhep.2017.11.009

Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real‐world setting

Christoph Höner zu Siederdissen, Peter Buggisch, Klaus H.W. Böker, Eckart Schott, Hartwig Klinker et al. (12 authors)

United European Gastroenterology Journal2017-06-1730 citations

10.1177/2050640617716607

Interventions

Group 1: Treatment of patients with cronic hepatitis c infection. Documentation of parameters from standard diagnostics, quality of life questionnaire (SF36) and (serious) adverse events.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 18 and chronic Hepatitis C Virus infection with viral replication (HCV-RNA +) Patients which are treated with the following antiviral therapies can be documented in the registry: elbasvir/grazoprevir (up to 3,000 patients); glecaprevir/pibrentasvir (up to 800 patients with active drug abuse and/or alcohol abuse and/or compensated liver cirrhosis (Child-Pugh A)); sofosbuvir/velpatasvir/voxilaprevir (exclusively as rescue therapy after DAA failure, up to 300 patients) Moreover, patients which are not treated can be documented in the registry. Patients are treated at the sole discretion of the physician.

Exclusion criteria

Exclusion criteria: Pregnancy (patient or female partner of male patient), women in nursing period or women of childbearing age without reliable contraception. Contraindications for use of antiviral treatment. Treatment of hepatitis c, which is conducted in clinial trials of phase I to IV must not be documented in the DHC-R. Patients whose hepatitis c treatment is documented in other remunerated non-interventional studies are not allowed to be documented simultaneously in the DHC-R.

Design outcomes

Primary

Measure	Time frame
Proportion of patients, who achieved sustained virological response 12 weeks after end of treatement (SVR12).	—

Secondary

Measure	Time frame
Safety & tolerability: all (severe) adverse events during treatment and follow-up period). virological outcome: RVR, EVR, EoTR, SVR24, on-treatment failure, viral relapse rates. Baseline including: Cirrhosis, previous therapy (if applicable), IL28B GT, BMI, Race, Age, viral genotype and viral load, rel-evant laboratory parameters, concomitant diseases. Adherence to therapy. Impact of successful therapy on morbidity and mortality on patients. Patient reported outcomes (based on patient questionnaires and clinical outcomes).	—

Measure

Time frame

Safety & tolerability: all (severe) adverse events during treatment and follow-up period). virological outcome: RVR, EVR, EoTR, SVR24, on-treatment failure, viral relapse rates. Baseline including: Cirrhosis, previous therapy (if applicable), IL28B GT, BMI, Race, Age, viral genotype and viral load, rel-evant laboratory parameters, concomitant diseases. Adherence to therapy. Impact of successful therapy on morbidity and mortality on patients. Patient reported outcomes (based on patient questionnaires and clinical outcomes).

—

Countries

Germany

Contacts

Public ContactYvonne Serfert

Leberstiftungs-GmbH Deutschland

info@leberstiftungs-gmbh.de05115326968

Outcome results

None listed